Sanofi SNY
NASDAQ SNY
$42.48 -0.66 (-1.53%)
At close: Sep 18, 2026 · 4:00 PM EDT

Sanofi (SNY) Income from Non-Controlling Interests (2009 - 2026)

Sanofi's (SNY) quarterly Income from Non-Controlling Interests came in at $39.5 million in Q2 2026, up 772.83% year-over-year from $4.5 million in Q2 2025, and up 462.61% quarter-over-quarter from $7.0 million in Q1 2026.

Analysis

Sanofi (SNY) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends

Sanofi has disclosed Income from Non-Controlling Interests across 18 years of filings, most recently posting $39.5 million for Q2 2026.

  • In Q2 2026, Income from Non-Controlling Interests rose 772.83% year-over-year to $39.5 million; the TTM figure through Jun 2026 stood at $61.8 million (down 13.26% YoY), while the FY2025 annual figure was $44.2 million, down 29.54% from the prior year.
  • Income from Non-Controlling Interests came in at $39.5 million for Q2 2026 at Sanofi, up from $7.0 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $58.2 million in Q4 2022 to a low of -$21.0 million in Q4 2025.
  • Average Income from Non-Controlling Interests over 5 years is $17.2 million, with a median of $13.6 million recorded in 2023.
  • Year-over-year, Income from Non-Controlling Interests plunged 263.4% in 2025 and surged 772.83% in 2026.
  • Over 5 years, Income from Non-Controlling Interests stood at $58.2 million in 2022, then sank by 105.55% to -$3.2 million in 2023, then jumped by 497.27% to $12.8 million in 2024, then sank by 263.4% to -$21.0 million in 2025, then jumped by 288.62% to $39.5 million in 2026.
  • Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $39.5 million in Q2 2026, $7.0 million in Q1 2026, and -$21.0 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn -
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn 3.00 Mn
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn -2.00 Mn
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn -7.00 Mn
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn 10.00 Mn
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn -1.00 Mn
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn 39.52 Mn
8 Revolution Medicines 40.91 Bn 40.91 Bn - -
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn -
10 Incyte 25.18 Bn 20.65 Bn 1.57 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 39.52 Mn
Mar 31, 2026 7.02 Mn
Dec 31, 2025 -20.95 Mn
Sep 30, 2025 36.24 Mn
Jun 30, 2025 4.53 Mn
Mar 31, 2025 22.09 Mn
Dec 31, 2024 12.82 Mn
Sep 30, 2024 31.85 Mn
Jun 30, 2024 4.31 Mn
Mar 31, 2024 14.12 Mn
Dec 31, 2023 -3.23 Mn
Sep 30, 2023 14.15 Mn
Jun 30, 2023 13.07 Mn
Mar 31, 2023 15.03 Mn
Dec 31, 2022 58.15 Mn
Sep 30, 2022 3.02 Mn
Jun 30, 2022 48.02 Mn
Mar 31, 2022 8.98 Mn
Dec 31, 2021 52.62 Mn
Sep 30, 2021 30.66 Mn